List of Tables
    Table 1. Spinal Muscular Atrophy Medicine CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Spinal Muscular Atrophy Medicine Market Trends
    Table 3. Spinal Muscular Atrophy Medicine Market Drivers
    Table 4. Spinal Muscular Atrophy Medicine Market Challenges
    Table 5. Spinal Muscular Atrophy Medicine Market Restraints
    Table 6. Global Spinal Muscular Atrophy Medicine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Spinal Muscular Atrophy Medicine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Spinal Muscular Atrophy Medicine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Spinal Muscular Atrophy Medicine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Spinal Muscular Atrophy Medicine Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Spinal Muscular Atrophy Medicine Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Spinal Muscular Atrophy Medicine Sales Share by Manufacturer, 2017-2022
    Table 15. Global Spinal Muscular Atrophy Medicine Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2021)
    Table 18. Top Players of Spinal Muscular Atrophy Medicine in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Spinal Muscular Atrophy Medicine Product Type
    Table 20. Date of International Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Spinal Muscular Atrophy Medicine Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Spinal Muscular Atrophy Medicine Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Spinal Muscular Atrophy Medicine Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Spinal Muscular Atrophy Medicine Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Spinal Muscular Atrophy Medicine Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Spinal Muscular Atrophy Medicine Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Spinal Muscular Atrophy Medicine Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Spinal Muscular Atrophy Medicine Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Spinal Muscular Atrophy Medicine Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Astellas Pharma Inc. Corporation Information
    Table 43. Astellas Pharma Inc. Description and Business Overview
    Table 44. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product
    Table 46. Astellas Pharma Inc. Recent Development
    Table 47. AveXis, Inc. Corporation Information
    Table 48. AveXis, Inc. Description and Business Overview
    Table 49. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 50. AveXis, Inc. Product
    Table 51. AveXis, Inc. Recent Development
    Table 52. Bioblast Pharma Ltd. Corporation Information
    Table 53. Bioblast Pharma Ltd. Description and Business Overview
    Table 54. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 55. Bioblast Pharma Ltd. Product
    Table 56. Bioblast Pharma Ltd. Recent Development
    Table 57. Cytokinetics, Inc. 24 Corporation Information
    Table 58. Cytokinetics, Inc. 24 Description and Business Overview
    Table 59. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 60. Cytokinetics, Inc. 24 Product
    Table 61. Cytokinetics, Inc. 24 Recent Development
    Table 62. F. Hoffmann-La Roche Ltd. Corporation Information
    Table 63. F. Hoffmann-La Roche Ltd. Description and Business Overview
    Table 64. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 65. F. Hoffmann-La Roche Ltd. Product
    Table 66. F. Hoffmann-La Roche Ltd. Recent Development
    Table 67. Genethon Corporation Information
    Table 68. Genethon Description and Business Overview
    Table 69. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 70. Genethon Product
    Table 71. Genethon Recent Development
    Table 72. Genzyme Corporation Corporation Information
    Table 73. Genzyme Corporation Description and Business Overview
    Table 74. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 75. Genzyme Corporation Product
    Table 76. Genzyme Corporation Recent Development
    Table 77. GMP-Orphan SAS Corporation Information
    Table 78. GMP-Orphan SAS Description and Business Overview
    Table 79. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 80. GMP-Orphan SAS Product
    Table 81. GMP-Orphan SAS Recent Development
    Table 82. Ionis Pharmaceuticals, Inc. Corporation Information
    Table 83. Ionis Pharmaceuticals, Inc. Description and Business Overview
    Table 84. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 85. Ionis Pharmaceuticals, Inc. Product
    Table 86. Ionis Pharmaceuticals, Inc. Recent Development
    Table 87. Longevity Biotech, Inc Corporation Information
    Table 88. Longevity Biotech, Inc Description and Business Overview
    Table 89. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 90. Longevity Biotech, Inc Product
    Table 91. Longevity Biotech, Inc Recent Development
    Table 92. Neurodyn Inc. Corporation Information
    Table 93. Neurodyn Inc. Description and Business Overview
    Table 94. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 95. Neurodyn Inc. Product
    Table 96. Neurodyn Inc. Recent Development
    Table 97. Neurotune AG Corporation Information
    Table 98. Neurotune AG Description and Business Overview
    Table 99. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 100. Neurotune AG Product
    Table 101. Neurotune AG Recent Development
    Table 102. Novartis AG Corporation Information
    Table 103. Novartis AG Description and Business Overview
    Table 104. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 105. Novartis AG Product
    Table 106. Novartis AG Recent Development
    Table 107. Sarepta Therapeutics, Inc. Corporation Information
    Table 108. Sarepta Therapeutics, Inc. Description and Business Overview
    Table 109. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. Sarepta Therapeutics, Inc. Product
    Table 111. Sarepta Therapeutics, Inc. Recent Development
    Table 112. Voyager Therapeutics, Inc. Corporation Information
    Table 113. Voyager Therapeutics, Inc. Description and Business Overview
    Table 114. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 115. Voyager Therapeutics, Inc. Product
    Table 116. Voyager Therapeutics, Inc. Recent Development
    Table 117. Vybion, Inc. Corporation Information
    Table 118. Vybion, Inc. Description and Business Overview
    Table 119. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 120. Vybion, Inc. Product
    Table 121. Vybion, Inc. Recent Development
    Table 122. WAVE Life Sciences Ltd. Corporation Information
    Table 123. WAVE Life Sciences Ltd. Description and Business Overview
    Table 124. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 125. WAVE Life Sciences Ltd. Product
    Table 126. WAVE Life Sciences Ltd. Recent Development
    Table 127. Key Raw Materials Lists
    Table 128. Raw Materials Key Suppliers Lists
    Table 129. Spinal Muscular Atrophy Medicine Customers List
    Table 130. Spinal Muscular Atrophy Medicine Distributors List
    Table 131. Research Programs/Design for This Report
    Table 132. Key Data Information from Secondary Sources
    Table 133. Key Data Information from Primary Sources
List of Figures
    Figure 1. Spinal Muscular Atrophy Medicine Product Picture
    Figure 2. Global Spinal Muscular Atrophy Medicine Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Spinal Muscular Atrophy Medicine Market Size 2017-2028 (US$ Million)
    Figure 4. Global Spinal Muscular Atrophy Medicine Sales 2017-2028 (K Pcs)
    Figure 5. United States Spinal Muscular Atrophy Medicine Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Spinal Muscular Atrophy Medicine Market Size 2017-2028 (US$ Million)
    Figure 7. United States Spinal Muscular Atrophy Medicine Sales 2017-2028 (K Pcs)
    Figure 8. United States Spinal Muscular Atrophy Medicine Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Spinal Muscular Atrophy Medicine Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Spinal Muscular Atrophy Medicine Report Years Considered
    Figure 11. Product Picture of LMI-070
    Figure 12. Product Picture of ND-602
    Figure 13. Product Picture of NT-1654
    Figure 14. Product Picture of Nusinersen
    Figure 15. Product Picture of NXD-30001
    Figure 16. Product Picture of Others
    Figure 17. Global Spinal Muscular Atrophy Medicine Market Share by Type in 2022 & 2028
    Figure 18. Global Spinal Muscular Atrophy Medicine Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 19. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2017-2028)
    Figure 20. Global Spinal Muscular Atrophy Medicine Sales by Type (2017-2028) & (K Pcs)
    Figure 21. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2017-2028)
    Figure 22. Global Spinal Muscular Atrophy Medicine Price by Type (2017-2028) & (USD/Pcs)
    Figure 23. United States Spinal Muscular Atrophy Medicine Market Share by Type in 2022 & 2028
    Figure 24. United States Spinal Muscular Atrophy Medicine Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 25. United States Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2017-2028)
    Figure 26. United States Spinal Muscular Atrophy Medicine Sales by Type (2017-2028) & (K Pcs)
    Figure 27. United States Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2017-2028)
    Figure 28. United States Spinal Muscular Atrophy Medicine Price by Type (2017-2028) & (USD/Pcs)
    Figure 29. Product Picture of Hospital
    Figure 30. Product Picture of Clinic
    Figure 31. Product Picture of Others
    Figure 32. Global Spinal Muscular Atrophy Medicine Market Share by Application in 2022 & 2028
    Figure 33. Global Spinal Muscular Atrophy Medicine Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 34. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2017-2028)
    Figure 35. Global Spinal Muscular Atrophy Medicine Sales by Application (2017-2028) & (K Pcs)
    Figure 36. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2017-2028)
    Figure 37. Global Spinal Muscular Atrophy Medicine Price by Application (2017-2028) & (USD/Pcs)
    Figure 38. United States Spinal Muscular Atrophy Medicine Market Share by Application in 2022 & 2028
    Figure 39. United States Spinal Muscular Atrophy Medicine Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 40. United States Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2017-2028)
    Figure 41. United States Spinal Muscular Atrophy Medicine Sales by Application (2017-2028) & (K Pcs)
    Figure 42. United States Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2017-2028)
    Figure 43. United States Spinal Muscular Atrophy Medicine Price by Application (2017-2028) & (USD/Pcs)
    Figure 44. North America Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 45. North America Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 46. U.S. Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Canada Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Europe Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 49. Europe Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 50. Germany Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. France Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. U.K. Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Italy Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Russia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 56. Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 57. China Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Japan Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. South Korea Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. India Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Australia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Taiwan Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Indonesia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Thailand Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Malaysia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Philippines Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Latin America Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 68. Latin America Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 69. Mexico Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Brazil Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Argentina Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Middle East & Africa Spinal Muscular Atrophy Medicine Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 73. Middle East & Africa Spinal Muscular Atrophy Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 74. Turkey Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Saudi Arabia Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. U.A.E Spinal Muscular Atrophy Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. Spinal Muscular Atrophy Medicine Value Chain
    Figure 78. Spinal Muscular Atrophy Medicine Production Process
    Figure 79. Channels of Distribution
    Figure 80. Distributors Profiles
    Figure 81. Bottom-up and Top-down Approaches for This Report
    Figure 82. Data Triangulation
    Figure 83. Key Executives Interviewed